The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
Moderna CEO Stephane Bancel sees his company’s product mix three years from now being 50% infectious diseases, 30% oncology, and 20% rare illnesses by revenue, virtually unchanged from what he envisioned two years ago despite its R&D retrenchment. Bancel shared…
To read the full story
Related Article
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
July 22, 2025
- Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
- Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…